Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer.
Reijm
E A
EA
Department of Medical Oncology, Erasmus MC/Daniel den Hoed Cancer Center/Josephine Nefkens Institute, Rotterdam, The Netherlands.
Jansen
M P H M
MP
Ruigrok-Ritstier
K
K
van Staveren
I L
IL
Look
M P
MP
van Gelder
M E Meijer
ME
Sieuwerts
A M
AM
Sleijfer
S
S
Foekens
J A
JA
Berns
E M J J
EM
D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology / Q000627:therapeutic use*; D015153:Blotting, Western; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D045744:Cell Line, Tumor; D004268:DNA-Binding Proteins / Q000235:genetics* / Q000378:metabolism; D000071221:Enhancer of Zeste Homolog 2 Protein; D004958:Estradiol / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D020847:Estrogen Receptor Modulators / Q000494:pharmacology / Q000627:therapeutic use; D047628:Estrogen Receptor alpha / Q000235:genetics* / Q000378:metabolism; D005260:Female; D005455:Fluorescent Antibody Technique; D020868:Gene Silencing; D006801:Humans; D009362:Neoplasm Metastasis; D063151:Polycomb Repressive Complex 2; D016133:Polymerase Chain Reaction; D053284:Polyunsaturated Alkamides / Q000494:pharmacology / Q000627:therapeutic use; D011379:Prognosis; D012333:RNA, Messenger / Q000235:genetics; D034741:RNA, Small Interfering; D013629:Tamoxifen / Q000494:pharmacology / Q000627:therapeutic use*; D014157:Transcription Factors / Q000235:genetics* / Q000378:metabolism; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D004268:DNA-Binding Proteins; D020847:Estrogen Receptor Modulators; D047628:Estrogen Receptor alpha; D053284:Polyunsaturated Alkamides; D012333:RNA, Messenger; D034741:RNA, Small Interfering; D014157:Transcription Factors; D013629:Tamoxifen; D004958:Estradiol; C051781:ICI 164384; C498409:EZH2 protein, human; D000071221:Enhancer of Zeste Homolog 2 Protein; D063151:Polycomb Repressive Complex 2